Valuation: Rigel Pharmaceuticals, Inc.

Market Cap 787M 689M 635M 587M 1.11B 75.08B 1.13B 7.59B 2.98B 36.99B 2.96B 2.89B 127B P/E 2026 *
12x
P/E 2027 * 12.3x
Enterprise Value 787M 689M 635M 587M 1.11B 75.08B 1.13B 7.59B 2.98B 36.99B 2.96B 2.89B 127B EV / Sales 2026 *
2.85x
EV / Sales 2027 * 2.38x
Free-Float
96.75%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Rigel Pharmaceuticals, Inc.

1 day-2.77%
1 week+9.89%
Current month+8.77%
1 month+37.66%
3 months+45.72%
6 months+4.19%
Current year-0.65%
1 week 38.8
Extreme 38.8
43.99
1 month 31.8
Extreme 31.8
43.99
Current year 24.95
Extreme 24.95
49.1
1 year 18.65
Extreme 18.65
52.24
3 years 7.12
Extreme 7.12
52.24
5 years 6.4
Extreme 6.4
52.24
10 years 6.4
Extreme 6.4
55
Manager TitleAgeSince
Chief Executive Officer 65 2014-11-20
Director of Finance/CFO 63 2018-05-28
Chief Tech/Sci/R&D Officer 65 2026-06-30
Director TitleAgeSince
Director/Board Member 71 1997-02-28
Director/Board Member 65 2014-11-20
Chairman 67 2022-04-30
Date Insider Type Main position Quantity % Market Cap.
06-21Sell

Director

-2,500 0.0135%
06-16Free

Compliance Officer

7,394 0.0400%
06-16Free

Chief Executive Officer

31,700 0.1713%
Change 5-day change 1-year change 3-year change Capi.($)
-2.77%+9.89%+117.09%+222.35% 787M
-2.33%-2.09%+50.33%+162.29% 1,060B
-0.82%-2.30%+62.97%+61.11% 619B
-0.73%-4.98%+27.22%+84.46% 438B
+0.33%-1.17%+27.98%+26.90% 333B
-0.02%-2.85%+25.27%+44.88% 282B
-3.89%-11.22%+20.78%+26.07% 267B
+0.66%-1.42%-29.26%-39.30% 218B
-0.06%-2.88%+20.98%+61.70% 196B
-3.72%-1.10%+13.35%+71.53% 161B
Average -1.08%-1.62%+33.67%+72.20% 357.47B
Weighted average by Cap. -0.57%-2.95%+35.30%+81.30%

Financials

2026 *2027 *
Net sales 277M 242M 223M 206M 391M 26.38B 398M 2.67B 1.05B 13B 1.04B 1.02B 44.68B 331M 289M 267M 247M 468M 31.56B 476M 3.19B 1.25B 15.55B 1.24B 1.22B 53.45B
Net income 70.19M 61.4M 56.63M 52.31M 99.25M 6.69B 101M 677M 266M 3.3B 264M 258M 11.34B 79.07M 69.16M 63.79M 58.92M 112M 7.54B 114M 762M 299M 3.72B 297M 290M 12.77B
Net Debt - -
Logo Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Employees
173
Date Price Change Volume
26-07-10 US$42.55 -2.77% 462,528
26-07-09 US$43.76 +1.93% 320,108
26-07-08 US$42.93 +0.87% 313,678
26-07-07 US$42.56 +5.73% 744,397
26-07-06 US$40.26 +3.96% 449,679
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
42.55USD
Average target price
54.20USD
Spread / Average Target
+27.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RIGL Stock